
Shield Therapeutics inks exclusive licence agreement in Japan
Shield Therapeutics said VITAL-NET will undertake and be responsible for all costs, including clinical and regulatory, related to activities required to achieve marketing authorisation and commercialisation of ACCRUFeR in Japan. The AIM-listed group stated …